Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
  • Patent number: 11987817
    Abstract: Disclosed is a process of manufacturing cell spheroids using a bioink. More particularly, provided is a method of manufacturing a cell spheroid, the method including extruding a first bioink including an alginate; extruding a second bioink including cells into the extruded first bioink; adding a calcium chloride (CaCl2) solution to the alginate included in the first bioink; and dissolving the second bioink, present in the first bioink, in a cell culture medium to form a cell spheroid from the cells.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 21, 2024
    Assignee: UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
    Inventors: Hyun Wook Kang, Seug Gyu Jeon, Jun Ho Heo
  • Patent number: 11980667
    Abstract: Trans-activating transcription (TAT) factor peptide oligomers coupled with functional agents can selectively complex to the anionic surface of cancerous cells. The TAT conjugates can be delivered to the locus of the tumors using intra-arterial injection during transient blood flow arrest.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 14, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Shailendra Joshi
  • Patent number: 11981919
    Abstract: The present invention relates to the field of stem cells. More specifically, the invention provides methods and compositions useful for forming three-dimensional human retinal tissue in vitro. In a specific embodiment, an in vitro method for differentiating hiPSCs into three-dimensional retinal tissue comprising functional photoreceptors comprises the steps of (a) culturing the hiPSCs to form aggregates; (b) transitioning the aggregates into a neural induction medium; (c) seeding the aggregates on to extracellular matrix coated cell culture substrates; (d) replacing NIM with a chemically-defined differentiation medium; (e) detaching NR domains; (f) culturing in suspension; and (g) adding animal serum or plasma component and retinoic acid.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: May 14, 2024
    Assignee: The John Hopkins University
    Inventors: Maria Valeria Canto-Soler, Xiufeng Zhong
  • Patent number: 11975030
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of lung disease, including at least chronic obstructive pulmonary disease (COPD). In particular cases, fibroblasts (including activated fibroblasts) and/or exosomes thereof are provided to an individual for the treatment of COPD. In particular cases the fibroblasts are activated and/or express one or more particular markers.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: May 7, 2024
    Assignee: Figene, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Patent number: 11975025
    Abstract: A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: May 7, 2024
    Assignee: IMMATICS US, INC.
    Inventors: Melinda Mata, Yannick Bulliard, Mamta Kalra
  • Patent number: 11970707
    Abstract: A strong insulator fragment from foamy virus, which can be used to insulate expression of a transgene and reduce genotoxicity of integrating vectors comprising such. The insulator fragment can also be used in gene targeting constructs in gene editing.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: April 30, 2024
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventor: Punam Malik
  • Patent number: 11973211
    Abstract: Disclosed is a process for producing graphene-metal nanowire hybrid material, comprising: (A) preparing a catalyst metal-coated mixture mass, which includes mixing graphene sheets with source metal particles to form a mixture and depositing a nanoscaled catalytic metal onto surfaces of the graphene sheets and/or metal particles; and (B) exposing the catalyst metal-coated mixture mass to a high temperature environment (preferably from 100° C. to 2,500° C.) for a period of time sufficient to enable a catalytic metal-catalyzed growth of multiple metal nanowires using the source metal particles as a feed material to form the graphene-metal nanowire hybrid material composition. An optional etching or separating procedure may be conducted to remove catalytic metal or graphene from the metal nanowires.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: April 30, 2024
    Assignee: Honeycomb Battery Company
    Inventor: Bor Z. Jang
  • Patent number: 11963982
    Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 23, 2024
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, Jennifer Leah Gori, Luis Barrera
  • Patent number: 11965017
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: April 23, 2024
    Assignee: InhibRx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Patent number: 11965021
    Abstract: The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 23, 2024
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Hong Liu, Pengbo Zhang, Lucas Horan, Yiyang Xu, Binnaz K. Staley, Lianxing Liu, Hongruo Yun
  • Patent number: 11964250
    Abstract: Methods and systems for synthesizing multicompartment capsules are disclosed, as well as multicompartment polymer capsules formed in accordance with disclosed techniques. At least one plurality of polymer capsules are formed via a capsule-forming process. A feed solution and a reservoir solution are provided, each comprising a biopolymer. The feed solution biopolymer and the reservoir solution biopolymer have opposite charges. Droplets of the feed solution are introduced into the reservoir solution, thereby forming via electrostatic complexation a plurality of polymer capsules. At least a portion of the resulting polymer capsules are then encapsulated in a larger polymer capsule via a similar process, wherein the feed solution utilized for the encapsulation process also comprises the formed smaller capsules.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 23, 2024
    Inventors: Hyuntaek Oh, Srinivasa R. Raghavan, William E. Bentley, Xi Lu, Jessica Lynn Terrell, So Hyun Ahn
  • Patent number: 11951128
    Abstract: The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cells alone or in combination with each other and/or additional therapies.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 9, 2024
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Hilde Cheroutre, Nicolas Thiault, Alexandre Larange, Hitoshi Iwaya
  • Patent number: 11952586
    Abstract: Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sonja Offner, Friederike Jung
  • Patent number: 11946070
    Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: April 2, 2024
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
  • Patent number: 11939376
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 26, 2024
    Assignee: Immatics Biotechnology GmbH
    Inventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • Patent number: 11939587
    Abstract: Provided is a plant or plant part comprising a polynucleotide encoding a mutant TriA polypeptide, the expression of the polynucleotide confers to the plant or plant part tolerance to herbicides.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: March 26, 2024
    Assignee: BASF SE
    Inventors: Doreen Schachtschabel, Eva Hollenbach, Mihiret Tekeste Sisay, Thomas Zierke, Danny Geerdink
  • Patent number: 11942223
    Abstract: Systems and methods for rapid gene set enrichment analysis and applications thereof are described. These systems and methods enable improved prioritization of relevant gene sets while maintaining a relatively lower false positive rate. Additionally, the ability to accelerate enrichment analysis and analyze hundreds of thousands of gene sets is described.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: March 26, 2024
    Assignee: Immuneering Corporation
    Inventor: Grigoriy Koytiger
  • Patent number: 11926808
    Abstract: An apparatus for collecting or culturing cells or cell colonies includes: a common substrate formed from a flexible resilient polymeric material and having a plurality of wells formed therein; and a plurality of rigid cell carriers releasably connected to said common substrate, with said carriers arranged in the form of an array, and with each of the carriers resiliently received in one of the wells. A method of collecting or culturing cells or cell colonies with such an apparatus is carried out by depositing a liquid media carrying cells on the apparatus so that said cells settle on or adhere to said the carriers; and then (c) releasing at least one selected carrier having said cells thereon by gradual application of release energy to each carrier from the cavity in which it is received (e.g., by pushing with a probe).
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 12, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Nancy L. Allbritton, Christopher E. Sims, Yuli Wang, Pavak Kirit Shah
  • Patent number: 11927589
    Abstract: According to the present disclosure, a technology for efficiently introducing a desired foreign substance from the outside of eukaryotic cells into at least the cytoplasm (and the nucleolus) of the cells is provided. A method disclosed here includes a step of preparing a construct for introducing a foreign substance including a carrier peptide fragment composed of any of amino acid sequences: KKRTLRKKKRKKR (SEQ ID NO: 1), KKRTLRKRRRKKR (SEQ ID NO: 2), KKRTLRKRKRKKR (SEQ ID NO: 3) and KKRTLRKKRRKKR (SEQ ID NO: 4), and a foreign substance that is bound to an N-terminal side and/or C-terminal side of the carrier peptide fragment, a step of supplying the construct for introducing a foreign substance to a sample containing desired eukaryotic cells, and a step of incubating the sample to which the construct for introducing a foreign substance is supplied and introducing the construct into eukaryotic cells in the sample.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: March 12, 2024
    Assignee: TOAGOSEI CO., LTD.
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Patent number: 11920169
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 5, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Patent number: 11922630
    Abstract: A device may receive images of a patient, and may perform segmentation of surfaces on the images to create a 3D model. The device may identify normal tissue regions and atrial fibrosis (AF) regions in the 3D model, and may divide the 3D model into the normal tissue regions and the AF regions. The device may assign first cell and tissue properties to the normal tissue regions, and may assign second cell and tissue properties to the AF regions. The device may perform simulations on the normal tissue regions and the AD regions, based on the first and second cell and tissue properties, to generate simulation results, and may extract first features from the simulation results. The device may extract second features from the images, and may process the first and second features, with a model, to select a feature that is predictive of atrial fibrillation recurrence.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 5, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Natalia Trayanova, Rheeda Ali, Julie Shade
  • Patent number: 11919946
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: March 5, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael C. Milone, Enxiu Wang
  • Patent number: 11913021
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: February 27, 2024
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • Patent number: 11910788
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 11913028
    Abstract: The present invention relates to artificial transcription factors (ATFs) that alter gene expression, including inducing pluripotency in cells or promoting the conversion of cells to specific cell fates. In particular, provided herein is a zinc-finger based ATF library that can be screened in cells by looking for expression of a specific gene (e.g., reporter expression), monitoring for cell surface markers or morphology, or via functional assays.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: February 27, 2024
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Asuka Eguchi, Aseem Z. Ansari
  • Patent number: 11913020
    Abstract: The present invention relates to a medium composition for improving stem cell migration, which includes ethionamide, and a use thereof. According to the present invention, the migration of stem cells may be effectively improved by the adjustment of a culture environment, which is a simple and safe method, without using gene manipulation or a viral vector, and the stem cells improved in migration by the method may be effectively used as a stem cell therapeutic agent that is able to function by rapidly migrating to the damaged region after transplantation.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: February 27, 2024
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
  • Patent number: 11912973
    Abstract: A bioreactor includes a scaffold, a scaffold support, and a manifold. The scaffold is seeded with a plurality of cells. The scaffold has an extended state and a non-extended state. The scaffold support that selectively modifies a state of the scaffold from the non-extended state to the extended state. A manifold is configured to provide a medium to the scaffold. The state of the scaffold from the non-extended state to the extended state is modified at a rate tuned to maintain a cell density associated with the plurality of cells within a particular density range.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: February 27, 2024
    Assignee: Ark Biotech Inc.
    Inventors: Zheng Huang, Orianna Elysse Kane, Xiaoting Liang, Natalie Rose Rubio
  • Patent number: 11904259
    Abstract: The present invention relates to a method for isolating extracellular vesicles using cations, and more particularly, to a method for isolating extracellular vesicles from various samples by using the affinity between the extracellular vesicles and cations. A method for isolating extracellular vesicles according to the present invention does not require expensive equipment, can be applied irrespective of sample amount, and has the advantage of being capable of efficiently isolating the extracellular vesicles while preserving the shape or characteristics thereof. Moreover, the method according to the present invention can be combined with existing isolation methods to maximize extracellular vesicle isolation efficiency, and can be applied to disease diagnosis, disease treatment, and multi-omics research using isolated extracellular vesicles, as well as to research on the properties of extracellular vesicles.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 20, 2024
    Assignee: ROSETTA EXOSOME
    Inventors: Yong Song Gho, Chang Jin Lee, Ji Hyun Kim, Sung Hyun Song
  • Patent number: 11905521
    Abstract: The present invention provides novel methods and systems, including cell lines, recombinant polynucleotide constructs, compositions, and kits, for targeted yet universal genomic manipulation.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2024
    Assignee: The Chinese University of Hong Kong
    Inventors: Bo Feng, Xiangjun He
  • Patent number: 11905515
    Abstract: Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: February 20, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic
  • Patent number: 11895994
    Abstract: Provided is a genetically modified non-human animal, in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said the non-human animal has been replaced by a nucleotide sequence encoding human Protein C or a functional fragment or variant thereof. Also provided are vectors, cells, and methods for the production of such non-human animals. Further provided are methods of testing agents for their ability to alter to the level and/or functional activity of human protein C, for example, to test their potential therapeutic efficacy.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: February 13, 2024
    Assignee: Shanghai RAAS Blood Products Co., Ltd.
    Inventors: Jun Xu, Lu Cheng, Yeheng Liu, Jiawei Yi, Xuefeng Zhou
  • Patent number: 11896974
    Abstract: A microfluidic device system includes a channel having an entrance and an exit, a height at the entrance being greater than a height at the exit. The height of the channel may decrease continuously from the height at the entrance to the height at the exit. Cells or particles or beads traveling through the channel become trapped based on their size and/or deformability. A visual sensor captures images of the trapped cells or particles or beads, and image software analyzes the captured images to provide size and/or deformability and/or fluorescence information. A method of fabricating such a microfluidic device includes introducing a glass wafer to an etching solution at a specific rate such that a first end of the glass wafer is etched longer than other portions of the glass wafer.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: February 13, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mark A. Burns, Alyse D. Krausz, Sarah Elizabeth Mena, Martin Patrick De Beer, Kevin R. Ward, Frederick Korley
  • Patent number: 11891421
    Abstract: The present invention relates to a variant of BPIFB4 protein (Bactericidal/Permeability Increasing protein family B, member 4) and to a polynucleotide or a vector encoding said variant of BPIFB4 protein and to their use for the treatment of pathologies involving impairment of nitric oxide signalling.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: February 6, 2024
    Assignee: LGVI S.R.L.
    Inventors: Annibale Alessandro Puca, Carmine Vecchione
  • Patent number: 11890300
    Abstract: The present invention provides an immune effector cell that comprises a chimeric antigen receptor (CAR) specific for a tag of a tagged polypeptide, wherein said polypeptide binds to an antigen of a target cell, and a chimeric costimulatory receptor (CCR) specific for a further antigen. The CCR is not able to mediate said immune response on its own but boosts the immune response of said immune effector cell triggered by the CAR.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 6, 2024
    Assignee: Miltenyi Biotec B.V. & Co. KG
    Inventors: Dominik Lock, Mario Assenmacher, Andrew Kaiser
  • Patent number: 11884932
    Abstract: Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of California
    Inventors: Cory R. Nicholas, John L. Rubenstein, Arnold R. Kriegstein, Arturo Alvarez-Buylla
  • Patent number: 11878999
    Abstract: This disclosure relates to the field of molecular biology. Provided are novel genes that encode pesticidal proteins. These pesticidal proteins and the nucleic acid sequences that encode them are useful in preparing pesticidal formulations and in the production of transgenic pest-resistant plants. Methods to create or alter pesticidal proteins are provided for altered or enhanced pesticidal activity.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: January 23, 2024
    Inventors: Ellaine Anne Mariano Fox, Naga Kishore Kakani, Kay Walter, Takashi Yamamoto, Yi Zheng
  • Patent number: 11872285
    Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: January 16, 2024
    Assignee: Life Technologies Corporation
    Inventors: Xavier de Mollerat du Jeu, Nektaria Andronikou
  • Patent number: 11866747
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: January 9, 2024
    Assignees: University of Miami, Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
  • Patent number: 11866685
    Abstract: Biocompatible, mechanically-dynamic thermoresponsive devices, methods for forming the devices, and exemplary applications for the devices are described. The devices include a series of wells therein and provide for temperature-controlled mechanostimulation of single cells or groups of cells that can be retained in the wells of a device. Mechanostimulation can be single instance of any duration, continuous, or regular or irregular cyclic mechanostimulation of single cells, cell clusters, cell spheroids, or organoids and may be utilized in any of a variety of biomedical applications including, without limitation, cellular engineering, cellular phenotyping, and drug discovery/screening.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: January 9, 2024
    Assignee: UNIVERSITY OF SOUTH CAROLINA
    Inventors: Ehsan Jabbarzadeh, Christopher Wu
  • Patent number: 11866726
    Abstract: Disclosed herein are genome editing systems and related methods which allow for the detection and quantitative measurement of all possible on-target gene editing outcomes, including targeted integration. The compositions and methods described herein rely on the use of donor templates comprising a 5? homology arm, a cargo, a one or more priming sites, a 3? homology arm, and optionally stuffer sequence.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 9, 2024
    Assignee: Editas Medicine, Inc.
    Inventors: Cecilia Cotta-Ramusino, Carrie M. Margulies
  • Patent number: 11857633
    Abstract: Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3? end to a phosphorothioate polymer. Attachment of the phosphorothioate polymer to the non-cell penetrating ribonucleic acid conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating ribonucleic acid. The nucleic acid conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer, inflammatory disease, and pain.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: January 2, 2024
    Assignee: City of Hope
    Inventors: Andreas Herrmann, Hua Yu
  • Patent number: 11858975
    Abstract: The present disclosure belongs to the field of biopharmaceuticals, and in particular, relates to a multi-domain active protein for treating metabolic diseases. The multi-domain active protein has a structural formula as shown in Formula I: A-La-F-Lb-B. The multi-domain active protein of the present disclosure has a long half-life and supports a once-a-week administration frequency. The GLP-1R agonist activity of the multi-domain active protein is increased up to over 200 times. The multi-domain active protein has good stability in vitro and in vivo, and shows low immunogenicity potential. As introduction of non-natural amino acids is not required and chemical synthesis and crosslinking steps are not involved, the multi-domain active protein can be prepared recombinantly. Therefore, the preparation process is greatly simplified.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 2, 2024
    Assignee: ZHEJIANG DOER BIOLOGICS CORPORATION
    Inventor: Yanshan Huang
  • Patent number: 11851662
    Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
    Type: Grant
    Filed: June 2, 2018
    Date of Patent: December 26, 2023
    Assignee: Ambrx, Inc.
    Inventors: Sigeng Chen, Yingchun Lu, Feng Tian
  • Patent number: 11850589
    Abstract: A system and method are provided for harvesting target biological substances. The system includes a substrate and a first and second channel formed in the substrate. The channels longitudinally extending substantially parallel to each other. A series of gaps extend from the first channel to the second channel to create a fluid communication path passing between a series of columns with the columns being longitudinally separated by a predetermined separation distance. The system also includes a first source configured to selectively introduce into the first channel a first biological composition at a first channel flow rate and a second source configured to selectively introduce into the second channel a second biological composition at a second channel flow rate. The sources are configured to create a differential between the first and second channel flow rates to generate physiological shear rates along the second channel that are bounded within a predetermined range.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: December 26, 2023
    Assignees: The Brigham and Women's Hospital, Inc., Boston, MA;, President and Fellows of Harvard College, Vilnius University
    Inventors: Joseph Italiano, Linas Mazutis, Jonathan N. Thon, David A. Weitz
  • Patent number: 11851679
    Abstract: Provided herein are reporter T-cells containing a reporter operably linked to the Nur77 locus. Also provided are methods for screening for an activity of a recombinant receptor, including those containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR), including assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells for one or more property or activity. The methods can be high-throughput.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: December 26, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Rupesh Amin, Aye Chen
  • Patent number: 11846635
    Abstract: The invention discloses an immunoglobulin-binding magnetic bead, comprising a porous matrix and one or more magnetic particles embedded in said matrix, wherein said matrix comprises a porous polymer and at least 10 mg/ml Fc-binding proteinaceous ligands covalently coupled to said porous polymer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 19, 2023
    Assignee: CYTIVA SWEDEN AB
    Inventors: Ola Lind, Klaus Gebauer, Eric Faldt, Nils Norrman, Ronnie Palmgren, Jesper Hedberg, Niklas Jungnelius, Karl Liderfelt, Anita Solbrand
  • Patent number: 11845952
    Abstract: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: December 19, 2023
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, TEIKA PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Okada, Tsutomu Igarashi, Asaka Shiozawa
  • Patent number: 11845935
    Abstract: Some embodiments of the invention include a nucleic acid molecule comprising natural nucleotides, non-natural nucleotides, an LNA which comprises one or more RNA core molecules, or an RNA molecule which comprises more than one RNA core molecule. Some embodiments of the invention include a nucleic acid molecule comprising an RNA molecule which comprises more than one RNA core molecule. Other embodiments of the invention include a nucleic acid molecule comprising a DNA molecule encoding the RNA molecule (e.g., vector or viral vector). Other embodiments include compositions or pharmaceutical compositions that comprise the nucleic acid molecule. Some embodiments of the invention comprise reducing miR-143 in a cell. Other embodiments of the invention include methods to deliver a protein across the BBB. Other embodiments include methods for treating disease (e.g., LSD, neuronopathic disease, neurodegenerative disease, Hurler syndrome, or MPS I). Additional embodiments of the invention are also discussed herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: December 19, 2023
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventor: Dao Pan
  • Patent number: 11844875
    Abstract: The invention relates to the field of tissue engineering and regenerative medicine, and particularly to a three-dimensional biomimetic tissue scaffold that exploits the use of three-dimensional print technology. Surface energy is controlled by precisely placing polymers with differing surface chemistry, and using surface texture and bulk composition to pattern absorbable and non-absorbable polymers for the purpose of promoting functional healing in a mammalian body.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: December 19, 2023
    Assignee: BVW Holding AG
    Inventors: Lukas Bluecher, Michael Milbocker
  • Patent number: 11841491
    Abstract: An observation vessel includes a holding portion configured to hold an observation object and an accommodation portion at least partially formed of a transparent curved surface and configured to position the holding portion. The holding portion is configured to hold the observation object at a set position separated from the curved surface toward a center of curvature of the curved surface in a first state of being positioned at a first position by the accommodation portion.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: December 12, 2023
    Assignee: Evident Corporation
    Inventors: Yoshihiro Shimada, Chihiro Hiraga, Katsunori Ogo, Daisuke Nishiwaki, Takashi Sugiyama